Referências
Principais artigos
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):512-21.Texto completo Resumo
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522-30.Texto completo Resumo
Wirrell EC, Nabbout R, Scheffer IE, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: report of the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022 Jun;63(6):1333-48.Texto completo Resumo
Hirsch E, French J, Scheffer IE, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022 Jun;63(6):1475-99.Texto completo Resumo
Gaillard WD, Chiron C, Cross JH, et al; ILAE Committee for Neuroimaging, Subcommittee for Pediatric Neuroimaging. Guidelines for imaging infants and children with recent-onset epilepsy. Epilepsia. 2009 Sep;50(9):2147-53.Texto completo Resumo
American College of Radiology. ACR appropriateness criteria: seizures and epilepsy. 2019 [internet publication].Texto completo
Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022 Jun;63(6):1349-97.Texto completo Resumo
Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022 Jun;63(6):1398-442.Texto completo Resumo
Kossoff EH, Zupec-Kania BA, Auvin S, et al; Charlie Foundation; Matthew's Friends; Practice Committee of the Child Neurology Society. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018 Jun;3(2):175-92.Texto completo Resumo
Artigos de referência
1. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):512-21.Texto completo Resumo
2. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522-30.Texto completo Resumo
3. Wirrell EC, Nabbout R, Scheffer IE, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: report of the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022 Jun;63(6):1333-48.Texto completo Resumo
4. Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015 Jun;17(2):117-23. Resumo
5. Eriksson KJ, Koivikko MJ. Prevalence, classification, and severity of epilepsy and epileptic syndromes in children. Epilepsia. 1997 Dec;38(12):1275-82.Texto completo Resumo
6. Ellis CA, Petrovski S, Berkovic SF. Epilepsy genetics: clinical impacts and biological insights. Lancet Neurol. 2020 Jan;19(1):93-100. Resumo
7. Hirsch E, French J, Scheffer IE, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022 Jun;63(6):1475-99.Texto completo Resumo
8. Kramer MA, Cash SS. Epilepsy as a disorder of cortical network organization. Neuroscientist. 2012 Aug;18(4):360-72.Texto completo Resumo
9. Destexhe A, McCormick DA, Sejnowski TJ. Thalamic and thalamocortical mechanisms underlying 3 Hz spike-and-wave discharges. Prog Brain Res. 1999;121:289-307. Resumo
10. Thurman DJ, Begley CE, Carpio A, et al. The primary prevention of epilepsy: a report of the Prevention Task Force of the International League Against Epilepsy. Epilepsia. 2018 May;59(5):905-14.Texto completo Resumo
11. Appleton RE, Demellweek C. Post-traumatic epilepsy in children requiring inpatient rehabilitation following head injury. J Neurol Neurosurg Psychiatry. 2002 May;72(5):669-72.Texto completo Resumo
12. Stafstrom CE, Staedtke V, Comi AM. Epilepsy mechanisms in neurocutaneous disorders: tuberous sclerosis complex, neurofibromatosis type 1, and Sturge-Weber syndrome. Front Neurol. 2017 Mar 17;8:87.Texto completo Resumo
13. Vestergaard M, Pedersen CB, Sidenius P, et al. The long-term risk of epilepsy after febrile seizures in susceptible subgroups. Am J Epidemiol. 2007 Apr 15;165(8):911-8.Texto completo Resumo
14. Berg AT, Shinnar S, Levy SR, et al. Childhood-onset epilepsy with and without preceding febrile seizures. Neurology. 1999 Nov 10;53(8):1742-8. Resumo
15. Waruiru C, Appleton R. Febrile seizures: an update. Arch Dis Child. 2004 Aug;89(8):751-6.Texto completo Resumo
16. Giovanardi Rossi P, Posar A, Parmeggiani A. Epilepsy in adolescents and young adults with autistic disorder. Brain Dev. 2000 Mar;22(2):102-6. Resumo
17. Steffenburg S, Steffenburg U, Gillberg C. Autism spectrum disorders in children with active epilepsy and learning disability: comorbidity, pre- and perinatal background, and seizure characteristics. Dev Med Child Neurol. 2003 Nov;45(11):724-30. Resumo
18. Koutroumanidis M, Arzimanoglou A, Caraballo R, et al. The role of EEG in the diagnosis and classification of the epilepsy syndromes: a tool for clinical practice by the ILAE Neurophysiology Task Force (Part 1). Epileptic Disord. 2017 Sep 1;19(3):233-98. Resumo
19. Koutroumanidis M, Arzimanoglou A, Caraballo R, et al. The role of EEG in the diagnosis and classification of the epilepsy syndromes: a tool for clinical practice by the ILAE Neurophysiology Task Force (Part 2). Epileptic Disord. 2017 Dec 1;19(4):385-437. Resumo
20. Panayiotopoulos CP. A clinical guide to epileptic syndromes and their treatment. 2nd ed. London, UK: Springer; 2007.
21. Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022 Jul;63(7):1761-77.Texto completo Resumo
22. Lu Y, Waltz S, Stenzel K, et al. Photosensitivity in epileptic syndromes of childhood and adolescence. Epileptic Disord. 2008 Jun;10(2):136-43. Resumo
23. Gaillard WD, Chiron C, Cross JH, et al; ILAE Committee for Neuroimaging, Subcommittee for Pediatric Neuroimaging. Guidelines for imaging infants and children with recent-onset epilepsy. Epilepsia. 2009 Sep;50(9):2147-53.Texto completo Resumo
24. Pressler R, Binnie CD, Cooper R, et al, eds. Neonatal and paediatric clinical neurophysiology. Edinburgh, UK: Churchill Livingstone; 2007.
25. Berg AT. Risk of recurrence after a first unprovoked seizure. Epilepsia. 2008;49(suppl 1):13-8. Resumo
26. Winckler MI, Rotta NT. Clinical and electroencephalographic follow-up after a first unprovoked seizure. Pediatr Neurol. 2004 Mar;30(3):201-6. Resumo
27. National Institute for Health and Care Excellence. Epilepsies in children, young people and adults. Apr 2022 [internet publication].Texto completo
28. MacCormick JM, McAlister H, Crawford J, et al. Misdiagnosis of long QT syndrome as epilepsy at first presentation. Ann Emerg Med. 2009 Jul;54(1):26-32. Resumo
29. American College of Radiology. ACR appropriateness criteria: seizures and epilepsy. 2019 [internet publication].Texto completo
30. Szaflarski JP, Gloss D, Binder JR, et al. Practice guideline summary: use of fMRI in the presurgical evaluation of patients with epilepsy. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2017 Jan 24;88(4):395-402.Texto completo Resumo
31. Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022 Jun;63(6):1349-97.Texto completo Resumo
32. Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022 Jun;63(6):1398-442.Texto completo Resumo
33. Wirrell EC, Shellhaas RA, Joshi C, et al; Pediatric Epilepsy Research Consortium (PERC). How should children with West syndrome be efficiently and accurately investigated? Results from the National Infantile Spasms Consortium. Epilepsia. 2015 Apr;56(4):617-25.Texto completo Resumo
34. Stephani U. The natural history of myoclonic astatic epilepsy (Doose syndrome) and Lennox-Gastaut syndrome. Epilepsia. 2006;47(suppl 2):53-5.Texto completo Resumo
35. Avbersek A, Sisodiya S. Does the primary literature provide support for clinical signs used to distinguish psychogenic nonepileptic seizures from epileptic seizures? J Neurol Neurosurg Psychiatry. 2010 Jul;81(7):719-25. Resumo
36. Stone J, Burton C, Carson A. Recognising and explaining functional neurological disorder. BMJ. 2020 Oct 21;371:m3745. Resumo
37. Brown RJ, Reuber M. Psychological and psychiatric aspects of psychogenic non-epileptic seizures (PNES): a systematic review. Clin Psychol Rev. 2016 Apr;45:157-82. Resumo
38. Dwivedi R, Ramanujam B, Chandra PS, et al. Surgery for drug-resistant epilepsy in children. N Engl J Med. 2017 Oct 26;377(17):1639-47.Texto completo Resumo
39. Perucca E, Perucca P, White HS, et al. Drug resistance in epilepsy. Lancet Neurol. 2023 Aug;22(8):723-34. Resumo
40. Gidal B, Klein P, Hirsch LJ. Seizure clusters, rescue treatments, seizure action plans: unmet needs and emerging formulations. Epilepsy Behav. 2020 Nov;112:107391.Texto completo Resumo
41. Mesraoua B, Abou-Khalil B, Hosni Khodair R, et al. Seizure clusters. J Drug Assess. 2021 Aug 14;10(1):86-90.Texto completo Resumo
42. Jafarpour S, Hirsch LJ, Gaínza-Lein M, et al. Seizure cluster: definition, prevalence, consequences, and management. Seizure. 2019 May;68:9-15.Texto completo Resumo
43. Leone MA, Giussani G, Nevitt SJ, et al. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. Cochrane Database Syst Rev. 2021 May 4;(5):CD007144.Texto completo Resumo
44. Hirtz D, Berg A, Bettis D, et al. Practice parameter: treatment of the child with a first unprovoked seizure. Neurology. 2003 Jan 28;60(2):166-75.Texto completo Resumo
45. Guerrini R, Zaccara G, la Marca G, et al. Safety and tolerability of antiepileptic drug treatment in children with epilepsy. Drug Saf. 2012 Jul 1;35(7):519-33. Resumo
46. Mula M, Kanner AM, Schmitz B, et al. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia. 2013 Jan;54(1):199-203.Texto completo Resumo
47. Kanner AM, Saporta AS, Kim DH, et al; Human Epilepsy Project. Mood and anxiety disorders and suicidality in patients with newly diagnosed focal epilepsy: an analysis of a complex comorbidity. Neurology. 2023 Mar 14;100(11):e1123-34.Texto completo Resumo
48. American College of Obstetricians and Gynecologists. Gynecologic management of adolescents and young women with seizure disorders: ACOG committee opinion, number 806. Obstet Gynecol. 2020 May;135(5):e213-20.Texto completo Resumo
49. European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. Mar 2018 [internet publication].Texto completo
50. Medicines and Healthcare products Regulatory Agency. Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review. Jan 2021 [internet publication].Texto completo
51. Dreier JW, Bjørk MH, Alvestad S, et al. Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders. JAMA Neurol. 2023 Jun 1;80(6):568-77. Resumo
52. Athar F, Ehsan M, Farooq M, et al. Adverse fetal and neonatal outcomes following in-utero exposure to oxcarbazepine: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022 Aug;88(8):3600-9.Texto completo Resumo
53. Bromley R, Adab N, Bluett-Duncan M, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2023 Aug 29;(8):CD010224.Texto completo Resumo
54. Medicines and Healthcare products Regulatory Agency. Pregabalin (Lyrica): findings of safety study on risks during pregnancy. Apr 2022 [internet publication].Texto completo
55. Bjørk MH, Zoega H, Leinonen MK, et al. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol. 2022 Jul 1;79(7):672-81.Texto completo Resumo
56. European Medicines Agency. New measures to avoid topiramate exposure in pregnancy. Oct 2023 [internet publication].Texto completo
57. Medicines and Healthcare products Regulatory Agency. Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure. Jul 2022 [internet publication].Texto completo
58. Robinson R. Vagal nerve stimulation is more effective than trials of further anti-epileptic drugs (AEDs) in children who have already tried >5 AEDs. Paper presented at: EPNS 2011 9th Congress of the European Paediatric Neurology Society. 11-14 May 2011. Dubrovnik, Croatia. Poster sessions: P14.3. Eur J Paediatr Neurol. 2011 May;15(suppl 1):89.
59. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg. 2011 Dec;115(6):1248-55. Resumo
60. Martin-McGill KJ, Bresnahan R, Levy RG, et al. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020 Jun 24;(6):CD001903.Texto completo Resumo
61. Kossoff EH, Zupec-Kania BA, Auvin S, et al; Charlie Foundation; Matthew's Friends; Practice Committee of the Child Neurology Society. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018 Jun;3(2):175-92.Texto completo Resumo
62. Morris GL 3rd, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy. Neurology. 2013 Oct 15;81(16):1453-9.Texto completo Resumo
63. Redgrave J, Day D, Leung H, et al. Safety and tolerability of transcutaneous vagus nerve stimulation in humans; a systematic review. Brain Stimul. 2018 Nov-Dec;11(6):1225-38. Resumo
64. Toffa DH, Touma L, El Meskine T, et al. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: a critical review. Seizure. 2020 Dec;83:104-23.Texto completo Resumo
65. Sheng J, Liu S, Qin H, et al. Drug-resistant epilepsy and surgery. Curr Neuropharmacol. 2018;16(1):17-28.Texto completo Resumo
66. Bok LA, Maurits NM, Willemsen MA, et al. The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy. Epilepsia. 2010 Dec;51(12):2406-11.Texto completo Resumo
67. Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia. 2015 Aug;56(8):1185-97.Texto completo Resumo
68. Ozawa H, Kawada Y, Noma S, et al. Oral high-dose phenobarbital therapy for early infantile epileptic encephalopathy. Pediatr Neurol. 2002 Mar;26(3):222-4. Resumo
69. Ohno M, Shimotsuji Y, Abe J, et al. Zonisamide treatment of early infantile epileptic encephalopathy. Pediatr Neurol. 2000 Oct;23(4):341-4. Resumo
70. Spoto G, Saia MC, Amore G, et al. Neonatal seizures: an overview of genetic causes and treatment options. Brain Sci. 2021 Sep 29;11(10):1295.Texto completo Resumo
71. Xu D, Chen S, Yang J, et al. Precision therapy with quinidine of KCNT1-related epileptic disorders: a systematic review. Br J Clin Pharmacol. 2022 Dec;88(12):5096-112.Texto completo Resumo
72. Malik SI, Galliani CA, Hernandez AW, et al. Epilepsy surgery for early infantile epileptic encephalopathy (Ohtahara syndrome). J Child Neurol. 2013 Dec;28(12):1607-17. Resumo
73. Nelson GR. Management of infantile spasms. Transl Pediatr. 2015 Oct;4(4):260-70.Texto completo Resumo
74. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev. 2013 Jun 5;(6):CD001770.Texto completo Resumo
75. O'Callaghan FJK, Edwards SW, Alber FD, et al; International Collaborative Infantile Spasms Study (ICISS) investigators. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2018 Oct;2(10):715-25.Texto completo Resumo
76. Northrup H, Aronow ME, Bebin EM, et al; International Tuberous Sclerosis Complex Consensus Group. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021 Oct;123:50-66.Texto completo Resumo
77. Grinspan ZM, Knupp KG, Patel AD, et al. Comparative effectiveness of initial treatment for infantile spasms in a contemporary US cohort. Neurology. 2021 Jul 15;97(12):e1217-28.Texto completo Resumo
78. Demarest ST, Shellhaas RA, Gaillard WD, et al; Pediatric Epilepsy Research Consortium. The impact of hypsarrhythmia on infantile spasms treatment response: observational cohort study from the National Infantile Spasms Consortium. Epilepsia. 2017 Dec;58(12):2098-103.Texto completo Resumo
79. Knupp KG, Leister E, Coryell J, et al; Pediatric Epilepsy Research Consortium. Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. Epilepsia. 2016 Nov;57(11):1834-42.Texto completo Resumo
80. O'Callaghan FJ, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017 Jan;16(1):33-42.Texto completo Resumo
81. Knupp KG, Coryell J, Nickels KC, et al; Pediatric Epilepsy Research Consortium. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol. 2016 Mar;79(3):475-84.Texto completo Resumo
82. Riikonen R, Mankinen K, Gaily E. Long-term outcome in pyridoxine-responsive infantile epilepsy. Eur J Paediatr Neurol. 2015 Nov;19(6):647-51. Resumo
83. Sahu JK, Madaan P, Prakash K. The landscape of infantile epileptic spasms syndrome in South Asia: peculiarities, challenges, and way forward. Lancet Reg Health Southeast Asia. 2023 May;12:100170.Texto completo Resumo
84. Banerjee A, Sahu JK, Sankhyan N, et al. Randomized trial of high-dose pyridoxine in combination with standard hormonal therapy in West syndrome. Seizure. 2021 Oct;91:75-80.Texto completo Resumo
85. Auvin S, Pandit F, De Bellecize J, et al. Benign myoclonic epilepsy in infants: electroclinical features and long-term follow-up of 34 patients. Epilepsia. 2006 Feb;47(2):387-93.Texto completo Resumo
86. Caraballo RH, Flesler S, Pasteris MC, et al. Myoclonic epilepsy in infancy: an electroclinical study and long-term follow-up of 38 patients. Epilepsia. 2013 Sep;54(9):1605-12.Texto completo Resumo
87. Oguni H. Symptomatic epilepsies imitating idiopathic generalized epilepsies. Epilepsia. 2005 Nov;46(suppl 9):84-90.Texto completo Resumo
88. Lagae L. Dravet syndrome. Curr Opin Neurol. 2021 Apr 1;34(2):213-8. Resumo
89. Gao C, Pielas M, Jiao F, et al. Epilepsy in Dravet syndrome - current and future therapeutic opportunities. J Clin Med. 2023 Mar 27;12(7):2532.Texto completo Resumo
90. Brigo F, Igwe SC, Bragazzi NL. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy. Cochrane Database Syst Rev. 2017 May 18;(5):CD010483.Texto completo Resumo
91. Zhang L, Li W, Wang C. Efficacy and safety of fenfluramine in patients with Dravet syndrome: a meta-analysis. Acta Neurol Scand. 2021 Apr;143(4):339-48. Resumo
92. National Institute for Health and Care Excellence. Fenfluramine for treating seizures associated with Dravet syndrome. Jul 2022 [internet publication].Texto completo
93. Lattanzi S, Brigo F, Trinka E, et al. Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020 Mar;34(3):229-41. Resumo
94. American Epilepsy Society. AES position statement on cannabis as a treatment for patients with epileptic seizures. Sep 2022 [internet publication].Texto completo
95. National Institute for Health and Care Excellence. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome. Dec 2019 [internet publication].Texto completo
96. Gunning B, Mazurkiewicz-Bełdzińska M, Chin RFM, et al. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta Neurol Scand. 2021 Feb;143(2):154-63.Texto completo Resumo
97. Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020 Jun;61(6):1090-8. Resumo
98. Nieto-Barrera M, Candau R, Nieto-Jimenez M, et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000 Dec;9(8):590-4. Resumo
99. Nickels K, Kossoff EH, Eschbach K, et al. Epilepsy with myoclonic-atonic seizures (Doose syndrome): clarification of diagnosis and treatment options through a large retrospective multicenter cohort. Epilepsia. 2021 Jan;62(1):120-7. Resumo
100. Nickels K, Thibert R, Rau S, et al; Pediatric Epilepsy Research Consortium. How do we diagnose and treat epilepsy with myoclonic-atonic seizures (Doose syndrome)? Results of the Pediatric Epilepsy Research Consortium survey. Epilepsy Res. 2018 Aug;144:14-9. Resumo
101. Joshi C, Nickels K, Demarest S, et al. Results of an international Delphi consensus in epilepsy with myoclonic atonic seizures/ Doose syndrome. Seizure. 2021 Feb;85:12-8.Texto completo Resumo
102. Brigo F, Jones K, Eltze C, et al. Anti-seizure medications for Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2021 Apr 7;(4):CD003277.Texto completo Resumo
103. Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018 Jul 10;91(2):82-90. Resumo
104. Cross JH, Auvin S, Falip M, et al. Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol. 2017 Sep 29;8:505.Texto completo Resumo
105. Montouris G, Aboumatar S, Burdette D, et al. Expert opinion: proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients. Epilepsy Behav. 2020 Sep;110:107146.Texto completo Resumo
106. Sharawat IK, Panda PK, Panda P, et al. Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: a systematic review and meta-analysis. Seizure. 2021 Oct;91:296-307.Texto completo Resumo
107. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Mar 17;391(10125):1085-96. Resumo
108. Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018 May 17;378(20):1888-97.Texto completo Resumo
109. National Institute for Health and Care Excellence. Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome. Dec 2019 [internet publication].Texto completo
110. Fazlollahi A, Zahmatyar M, ZareDini M, et al. Adverse events of cannabidiol use in patients with epilepsy: a systematic review and meta-analysis. JAMA Netw Open. 2023 Apr 3;6(4):e239126.Texto completo Resumo
111. Knupp KG, Scheffer IE, Ceulemans B, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022 Jun 1;79(6):554-64.Texto completo Resumo
112. Knupp KG, Scheffer IE, Ceulemans B, et al. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 2023 Jan;64(1):139-51.Texto completo Resumo
113. Agashe S, Worrell G, Britton J, et al. Cenobamate in generalized epilepsy and combined generalized and focal epilepsy. Neurol Clin Pract. 2023 Apr;13(2):e200133.Texto completo Resumo
114. Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for Lennox-Gastaut syndrome: current and future strategies. CNS Drugs. 2021 Jan;35(1):61-83.Texto completo Resumo
115. Brigo F, Igwe SC, Lattanzi S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev. 2021 Jan 21;(1):CD003032.Texto completo Resumo
116. Nevitt SJ, Sudell M, Cividini S, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2022 Apr 1;(4):CD011412.Texto completo Resumo
117. Glauser TA, Cnaan A, Shinnar S, et al; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.Texto completo Resumo
118. Coppola G, Auricchio G, Federico R, et al. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia. 2004 Sep;45(9):1049-53.Texto completo Resumo
119. Rinaldi VE, Di Cara G, Mencaroni E, et al. Therapeutic options for childhood absence epilepsy. Pediatr Rep. 2021 Dec 16;13(4):658-67.Texto completo Resumo
120. Trinka E, Alsaadi T, Goji H, et al. Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice. Epilepsia. 2023 Aug;64(8):2094-107.Texto completo Resumo
121. Operto FF, Orsini A, Sica G, et al. Perampanel and childhood absence epilepsy: a real life experience. Front Neurol. 2022 Aug 11;13:952900.Texto completo Resumo
122. Trudeau V, Myers S, LaMoreaux L, et al. Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol. 1996 Nov;11(6):470-5. Resumo
123. Zanzmera P, Menon RN, Karkare K, et al. Epilepsy with myoclonic absences: electroclinical characteristics in a distinctive pediatric epilepsy phenotype. Epilepsy Behav. 2016 Nov;64(pt a):242-7. Resumo
124. Smith KM, Wirrell EC, Andrade DM, et al. Management of epilepsy with eyelid myoclonia: results of an international expert consensus panel. Epilepsia. 2023 Sep;64(9):2342-50.Texto completo Resumo
125. Zawar I, Knight EP. Epilepsy with eyelid myoclonia (Jeavons syndrome). Pediatr Neurol. 2021 Aug;121:75-80. Resumo
126. Smith KM, Youssef PE, Wirrell EC, et al. Jeavons syndrome: clinical features and response to treatment. Pediatr Neurol. 2018 Sep;86:46-51. Resumo
127. Petropoulos MC, Bonaiuto K, Currier J, et al. Practical aspects of childhood epilepsy. BMJ. 2019 Nov 11;367:l6096. Resumo
128. Bresnahan R, Panebianco M, Marson AG. Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures. Cochrane Database Syst Rev. 2020 Jul 1;(7):CD007783.Texto completo Resumo
129. Caraballo R, Silva S, Beltran L, et al. Childhood-only epilepsy with generalized tonic-clonic seizures: a well-defined epileptic syndrome. Epilepsy Res. 2019 Jul;153:28-33. Resumo
130. Ji ZY, Huang YQ, He WZ. Sodium valproate combined with topiramate vs. sodium valproate alone for refractory epilepsy: a systematic review and meta-analysis. Front Neurol. 2022 Jan 5:12:794856.Texto completo Resumo
131. Murphy K, Delanty N. Primary generalized epilepsies. Curr Treat Options Neurol. 2000 Nov;2(6):527-42. Resumo
132. Cross JH. Pitfalls in the diagnosis and differential diagnosis of epilepsy. Paediatr Child Health. 2009 May;19(5):199-202.Texto completo
133. Kostov H, Larsson PG, Roste GK. Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalized epilepsy? Acta Neurol Scand Suppl. 2007;187:55-8. Resumo
134. Trevathan E, Kerls SP, Hammer AE, et al. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Pediatrics. 2006 Aug;118(2):e371-8. Resumo
135. Sharpe DV, Patel AD, Abou-Khalil B, et al. Levetiracetam monotherapy in juvenile myoclonic epilepsy. Seizure. 2008 Jan;17(1):64-8. Resumo
136. Verrotti A, Cerminara C, Coppola G, et al. Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents. Dev Med Child Neurol. 2008 Jan;50(1):29-32. Resumo
137. Serafini A, Gerard E, Genton P, et al. Treatment of juvenile myoclonic epilepsy in patients of child-bearing potential. CNS Drugs. 2019 Mar;33(3):195-208. Resumo
138. Tennis P, Eldridge RR; International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia. 2002 Oct;43(10):1161-7.Texto completo Resumo
139. Bourgeois BF. Chronic management of seizures in the syndromes of idiopathic generalized epilepsy. Epilepsia. 2003 Mar;44 Suppl 2:27-32.Texto completo Resumo
140. Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord. 2004 Dec;6(4):267-70.Texto completo Resumo
141. Kessler SK, McGinnis E. A practical guide to treatment of childhood absence epilepsy. Paediatr Drugs. 2019 Feb;21(1):15-24.Texto completo Resumo
142. French JA, Krauss GL, Wechsler RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology. 2015 Sep 15;85(11):950-7.Texto completo Resumo
143. Marson AG, Al-Kharusi AM, Alwaidh M, et al; SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007 Mar 24;369(9566):1016-26.Texto completo Resumo
144. Wheless JW. Use of topiramate in childhood generalized seizure disorders. J Child Neurol. 2000;15(suppl 1):S7-13. Resumo
145. Wheless JW, Neto W, Wang S; EPMN-105 Study Group. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol. 2004 Feb;19(2):135-41. Resumo
146. Boon P, Ferrao Santos S, Jansen AC, et al. Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update. Acta Neurol Belg. 2021 Feb;121(1):241-57.Texto completo Resumo
147. Gloss D, Pargeon K, Pack A, et al. Antiseizure medication withdrawal in seizure-free patients: practice advisory update summary: report of the AAN guideline subcommittee. Neurology. 2021 Dec 7;97(23):1072-81.Texto completo Resumo
148. Ayuga Loro F, Gisbert Tijeras E, Brigo F. Rapid versus slow withdrawal of antiepileptic drugs. Cochrane Database Syst Rev. 2022 Jan 10;(1):CD005003.Texto completo Resumo
149. De SK. Ganaxolone: first FDA-approved medicine for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. Curr Med Chem. 2024;31(4):388-92.Texto completo Resumo
150. Olson HE, Demarest ST, Pestana-Knight EM, et al. Cyclin-dependent kinase-like 5 deficiency disorder: clinical review. Pediatr Neurol. 2019 Aug;97:18-25.Texto completo Resumo
151. Hahn CD, Jiang Y, Villanueva V, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA). Epilepsia. 2022 Oct;63(10):2671-83.Texto completo Resumo
152. Tolete P, Knupp K, Karlovich M, et al. Lorcaserin therapy for severe epilepsy of childhood onset: a case series. Neurology. 2018 Oct 30;91(18):837-9.Texto completo Resumo
153. ClinicalTrials.gov. A study of lorcaserin as adjunctive treatment in participants with Dravet syndrome (MOMENTUM 1). NCT04572243. Jun 2023 [internet publication].Texto completo
154. ClinicalTrials.gov. Carisbamate in adult and pediatric subjects with Lennox-Gastaut syndrome. NCT03731715. May 2023 [internet publication].Texto completo
155. ClinicalTrials.gov. Carisbamate safety study in adult and pediatric subjects with Lennox-Gastaut syndrome. NCT04062981. May 2023 [internet publication].Texto completo
156. ClinicalTrials.gov. Investigate efficacy and safety of carisbamate as adjunctive treatment for seizures associated with LGS in children and adults. NCT05219617. Nov 2023 [internet publication].Texto completo
157. Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): I. Drugs in preclinical and early clinical development. Epilepsia. 2022 Nov;63(11):2865-82. Resumo
158. ClinicalTrials.gov. An open-label extension of the study XEN496 (Ezogabine) in Children With KCNQ2-DEE (EPIK-OLE). NCT04912856. Jun 2023 [internet publication].Texto completo
159. He Z, Li Y, Zhao X, et al. Dravet syndrome: advances in etiology, clinical presentation, and treatment. Epilepsy Res. 2022 Dec;188:107041. Resumo
160. Nelson JA, Knupp KG. Lennox-Gastaut syndrome: current treatments, novel therapeutics, and future directions. Neurotherapeutics. 2023 Sep;20(5):1255-62. Resumo
161. ClinicalTrials.gov. An open-label study to investigate the safety of single and multiple ascending doses in children and adolescents with Dravet syndrome. NCT04442295. Nov 2023 [internet publication].Texto completo
162. ClinicalTrials.gov. An open-label extension study of STK-001 for patients with Dravet syndrome. NCT04740476. Nov 2023 [internet publication].Texto completo
163. Lundstrom BN, Osman GM, Starnes K, et al. Emerging approaches in neurostimulation for epilepsy. Curr Opin Neurol. 2023 Apr 1;36(2):69-76. Resumo
164. Haneef Z, Skrehot HC. Neurostimulation in generalized epilepsy: a systematic review and meta-analysis. Epilepsia. 2023 Apr;64(4):811-20. Resumo
165. Gummadavelli A, Englot DJ, Schwalb JM, et al; American Society for Stereotactic and Functional Neurosurgeons. ASSFN position statement on deep brain stimulation for medication-refractory epilepsy. Neurosurgery. 2022 May 1;90(5):636-41.Texto completo Resumo
166. Walton D, Spencer DC, Nevitt SJ, et al. Transcranial magnetic stimulation for the treatment of epilepsy. Cochrane Database Syst Rev. 2021 Apr 15;(4):CD011025.Texto completo Resumo
167. Simula S, Daoud M, Ruffini G, et al. Transcranial current stimulation in epilepsy: a systematic review of the fundamental and clinical aspects. Front Neurosci. 2022 Aug 25;16:909421.Texto completo Resumo
168. Hauser E, Freilinger M, Seidl R, et al. Prognosis of childhood epilepsy in newly referred patients. J Child Neurol. 1996 May;11(3):201-4. Resumo
169. Ramos Lizana J, Cassinello Garcia E, Carrasco Marina LL, et al. Seizure recurrence after a first unprovoked seizure in childhood: a prospective study. Epilepsia. 2000 Aug;41(8):1005-13.Texto completo Resumo
170. Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain. 2006 Mar;129(Pt 3):617-24.Texto completo Resumo
171. Guery D, Rheims S. Clinical management of drug resistant epilepsy: a review on current strategies. Neuropsychiatr Dis Treat. 2021 Jul 12;17:2229-42.Texto completo Resumo
172. McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005 Jul 16-22;366(9481):205-10. Resumo
173. Holsti M, Sill BL, Firth SD, et al. Prehospital intranasal midazolam for the treatment of pediatric seizures. Pediatr Emerg Care. 2007 Mar;23(3):148-53. Resumo
174. Harden C, Tomson T, Gloss D, et al; American Academy of Neurology, American Epilepsy Society. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors. Neurology. 2017 Apr 25;88(17):1674-80.Texto completo Resumo
175. Pensel MC, Nass RD, Taubøll E, et al. Prevention of sudden unexpected death in epilepsy: current status and future perspectives. Expert Rev Neurother. 2020 May;20(5):497-508. Resumo
176. Wilson SJ, Baxendale S, Barr W, et al. Indications and expectations for neuropsychological assessment in routine epilepsy care: report of the ILAE Neuropsychology Task Force, Diagnostic Methods Commission, 2013-2017. Epilepsia. 2015 May;56(5):674-81.Texto completo Resumo
177. Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016 Jan;15(1):106-15. Resumo
178. Hesdorffer DC, Ishihara L, Mynepalli L, et al. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol. 2012 Aug;72(2):184-91. Resumo
179. Patel AD, Baca C, Franklin G, et al. Quality improvement in neurology: Epilepsy Quality Measurement Set 2017 update. Neurology. 2018 Oct 30;91(18):829-36.Texto completo Resumo
180. Maguire MJ, Marson AG, Nevitt SJ. Antidepressants for people with epilepsy and depression. Cochrane Database Syst Rev. 2021 Apr 16;(4):CD010682.Texto completo Resumo
181. Cheng LS, Prasad AN, Rieder MJ. Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents. Can J Clin Pharmacol. 2010 Winter;17(1):e5-46. Resumo
182. American Epilepsy Society. Substitution of different formulations of antiseizure medication for the treatment of epilepsy. Aug 2023 [internet publication].Texto completo
183. Fleeman N, Bradley PM, Panebianco M, et al. Care delivery and self-management strategies for children with epilepsy. Cochrane Database Syst Rev. 2022 Apr 27;(4):CD006245.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal